Biotest Investor Conference comments on BT-062 -- More guaranteed Immunogen good news to follow in December...


http://www.immunogen.com/wt/page/other

http://irpages2.equitystory.com/biotest/...

BT-062 discussed about 75% through the webcast:

Maximum tolerated dose achieved at 7th dosing level

several patients have achieved stable disease

other patients have seen partial response

phase II trial to begin in 2010 with more participating centers and patients
results of current study to be published in at ASH meeting in New Orleans in December

http://www.hematology.org/Meetings/Annua...